Ertugliflozin in Patients with Stage 3 Chronic Kidney Disease and Type 2 Diabetes Mellitus: The VERTIS RENAL Randomized Study

INTRODUCTION: Ertugliflozin is a sodium-glucose cotransporter 2 inhibitor in development for type 2 diabetes mellitus (T2DM). The safety and efficacy of ertugliflozin were evaluated over 52 weeks in patients with chronic kidney disease (CKD). METHODS: In this double-blind randomized study (NCT019868...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Diabetes Ther
Asıl Yazarlar: Grunberger, George, Camp, Sarah, Johnson, Jeremy, Huyck, Susan, Terra, Steven G., Mancuso, James P., Jiang, Zhi Wei, Golm, Gregory, Engel, Samuel S., Lauring, Brett
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Springer Healthcare 2017
Konular:
Original Research
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC5801223/
https://ncbi.nlm.nih.gov/pubmed/29159457
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s13300-017-0337-5
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller